protein therapeutics

Zai Lab and Crescendo Biologics have entered a worldwide licensing agreement for the development, commercialisation and manufacture of innovative protein therapeutics for inflammatory indications. Read more


Aprea Therapeutics, Karolinska Development’s portfolio company, has announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246. Read more


Integrating an Integra VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins. Read more